

Detecting COVID-19 and other respiratory infections in obstructive sleep apnoea patients through CPAP device telemonitoring

Digital Health
Volume 7: 1–4
© The Author(s) 2021
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/20552076211002957
journals.sagepub.com/home/dhj



Jean-Louis Pépin^{1,2,*} , Sébastien Bailly^{1,2,*}, Jean-Christian Borel³,
Sophie Logerot³, Marc Sapène⁴, Jean-Benoît Martinot^{5,6}, Patrick Lévy^{1,2,†}
and Renaud Tamisier^{1,2,†}

Abstract

Objective: The earliest possible detection of individuals with COVID-19 has been essential to curb the spread of infection. Existing digital tools have been scaled up to address this issue. Every night telemonitoring data on continuous positive airway pressure (CPAP) device use, the first-line therapy for obstructive sleep apnoea (OSA), is collected worldwide. We asked whether the changes in CPAP adherence patterns of might constitute an alert for COVID-19.

Methods: We analysed preliminary results of telemonitoring data, recorded between February 1 and April 30, 2020, on OSA patients followed by our sleep clinics and diagnosed with COVID-19.

Results: CPAP telemonitoring data from the first 19 patients diagnosed with COVID-19 showed a clear decrease or halt in adherence in the 20 days immediately preceding COVID-19 diagnosis compared to an earlier period ($p < 0.01$).

Conclusion: Patterns of continuous positive airway pressure device use by obstructive sleep apnoea patients collected through telemonitoring can indicate the onset of COVID-19 symptoms. Existing telemonitoring platforms could be immediately used to screen for COVID-19, and for other respiratory infections, in this large at-risk population.

Keywords

Continuous positive airway pressure, telemonitoring, COVID, detection

Submission date: 1 February 2021; Acceptance date: 22 February 2021

Introduction

To slow the spread of the current coronavirus (COVID-19) pandemic it has been crucial to prioritize early identification of infected subjects to quarantine patients and their entourage.

In the context of the pandemic various digital tools have been scaled-up to address this issue including population-wide surveys, online¹ or via social media,^{2,3} and the exponential development of telemedicine with video consultations. The primary goal has been the early screening of already symptomatic patients to minimize pressure on healthcare facilities, and to protect health care personnel and other members of the community. We propose *that existing*

¹HP2 Laboratory, INSERM U1042, University Grenoble Alpes, Grenoble, France

²EFCR Laboratory, Grenoble Alpes University Hospital, Grenoble, France

³AGIR à dom. Homecare Charity, Meylan, France

⁴Sleep Apnea Exploration Unit, Bel-Air Clinic, Bordeaux, France

⁵Sleep Laboratory, CHU UCL Namur Site Sainte-Elisabeth, Namur, Belgium

⁶Institute of Experimental and Clinical Research, UCL, Bruxelles Woluwe, Belgium

*These authors are co-first authors.

†These authors are co-senior authors.

Corresponding author:

Jean-Louis Pépin, Laboratoire EFCR, CHU de Grenoble Alpes, CS10217, 38043 Grenoble, France.

Email: JPepin@chu-grenoble.fr



telemonitoring platforms for the follow-up of sleep apnoea could be used as a resource to assist screening by overstretched health providers. In France, the national healthcare system actively promotes and reimburses telemonitoring of continuous positive airway pressure (CPAP) device use, the first-line therapy for obstructive sleep apnoea (OSA).^{4,5} Every night CPAP devices transmit the residual apnoea-hypopnea index (AHI) and adherence making relevant information continuously available to clinicians and homecare providers for real-time patient follow-up (Figure 1). To date, over 1.2 million people throughout France and more than 10 million worldwide use CPAP telemonitoring.

It is particularly important to screen for signs of COVID-19 in the OSA population for two essential reasons: (i) CPAP treatment is considered as a high-risk aerosol-generating procedure potentially facilitating virus dispersion into the environment and transmission of infection to families;⁶ (ii) OSA is a multi-morbid disease with up to 70% of patients being obese and having a high prevalence of cardiovascular and metabolic comorbidities. This context is known to greatly favour the occurrence of “cytokine storm” syndrome and severe inflammation processes that are the main mechanisms underlying fatal forms of COVID-19. Adults with OSA are thus more susceptible to severe COVID-19 outcomes owing to their clusters of comorbidities.^{7,8}

We hypothesized that symptoms associated with COVID-19, i.e. cough, fever, headache, diarrhoea,

rhinorrhoea or nasal congestion, and nausea or vomiting would significantly alter CPAP usage leading to an abrupt reduction in adherence or discontinuation of treatment. In OSA patients with long-lasting good CPAP adherence, the sudden appearance in telemonitoring data of such adherence patterns might constitute an alert for COVID-19.

Methods

We analysed preliminary results of telemonitoring data, recorded between February 1 and April 30, 2020, on the first nineteen OSA patients followed by our sleep clinics and diagnosed with COVID-19 (eight hospitalizations, one death). As for all patients with CPAP telemonitoring, authorization and privacy issues had already been solved through signed patient consent and secured data access restricted to homecare providers and physicians.

Results

For the whole group there was a significant decrease in CPAP adherence when comparing the periods Day -40 to Day -21 versus Day -20 to Day 0 before COVID-19 diagnosis ($p < 0.01$). Figure 2 shows the evolution of adherence through individual day by day patterns of CPAP use (mean $\pm$ SE) in six OSA patients. We retrospectively phoned patients and they indicated that




Figure 1. CPAP telemonitoring.




Figure 2. Patterns of CPAP use by six exemplary patients in the days preceding COVID-19 diagnosis C+: COVID-19 diagnosis, H: Hospitalization.

changes in CPAP usage were mainly driven by respiratory issues and/or the need for hospitalization.

Discussion

Our data clearly demonstrate that symptomatic COVID-19 is generally associated with an abrupt modification of CPAP adherence that is easy to identify in regular CPAP users. Our results are preliminary but have high potential for the wide-scale deployment of CPAP telemonitoring as a screening tool in the OSA population in many countries.

The pattern of reducing adherence or completely stopping CPAP treatment might be related to not only the burden of symptoms and severity of the disease but also to the concern by patients to reduce the risk of virus transmission to other household members through aerosolization. Early identification of the situation, in the absence of need for hospitalisation, could facilitate immediate self-isolation in another bedroom and implementation by homecare providers of non-vented masks with a virus filter, reducing the spread significantly during CPAP treatment.⁹ A limitation of CPAP telemonitoring in the COVID-19 context, and shared with all screening procedures, is that cases of infection can go undetected because of lack of symptoms. The use of artificial intelligence with embedded alerts¹⁰ could give rapid and accurate CPAP telemonitoring interpretations, triggering an investigation by the physician, improving workflow and limiting

transmission. We acknowledge that the pattern of abrupt reduction in CPAP adherence is probably not COVID-19 specific and might be due to other respiratory infections. Likewise patients with erratic patterns of CPAP use might generate false alerts. For further research, a control group (without COVID-19 infection) should be included, allowing to determine sensitivity, specificity, and the optimal cut-off level for “reduction of average nightly CPAP-use” to detect COVID-19 infection.

The fact that OSA is one of the most prevalent chronic diseases affecting nearly one billion people worldwide¹¹ and that CPAP telemonitoring is currently used by millions of patients in many countries, makes the use of CPAP telemonitoring for screening for COVID-19 and for other respiratory infections, such as seasonal influenza, an attractive strategy in this large at-risk population. To develop the concept of screening for respiratory infections through telemonitoring, we urge other countries and a consortium of CPAP companies and homecare providers to share CPAP telemonitoring data and to build international collaborations for the development of methods, risk models and alert systems generated by artificial intelligence.

Acknowledgements: We would like to thank Alison Foote (Grenoble Alpes University Hospital, France) for critically editing the manuscript.

Contributorship: JLP and RT conceived the study. JCB, SL, MS, JCM and RT screened CPAP monitoring and patient data, SB performed the data analysis. JLP and JCB wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JLP reports grants from Air Liquide Foundation, grants and personal fees from Agiradom, grants and personal fees from AstraZeneca, grants from Fisher and Paykel, grants from Mutualia, grants and personal fees from Philips, grants and personal fees from Resmed, grants from Vitalaire, grants from Boehringer Ingelheim, grants from Jazz Pharmaceuticals, grants from Night Balance, grants from Sefam, outside the submitted work; SL and JCB are employees of AGiR-à-dom, a French home-care provider; RT reports other from Agir-a-dom, grants from Resmed, outside the submitted work; SB, MS, JBM and PL have no conflict of interest directly related to this work

Ethical approval: As for all patients with CPAP telemonitoring, authorization and privacy issues had already been solved through signed patient consent and secured data access restricted to homecare providers and physicians.

Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: JLP, RT and SB are supported by the French National Research Agency in the framework of the “Investissements d’avenir” program (ANR-15-IDEX-02) and the “e-health and integrated care and trajectories medicine and MIAI artificial intelligence” Chairs of excellence from the Grenoble Alpes University Foundation. This work has been partially supported by MIAI @ Grenoble Alpes, (ANR-19-P3IA-0003).

Guarantor: JLP

ORCID iD: Jean-Louis Pépin  <https://orcid.org/0000-0003-3832-2358>

Peer review: This manuscript was reviewed by reviewers who have chosen to remain anonymous.

References

1. Rossman H, Keshet A, Shilo S, et al. A framework for identifying regional outbreak and spread of COVID-19 from one-minute population-wide surveys. *Nat Med* 2020; 26: 634–638.
2. Nelson LM, Simard JF, Oluyomi A, et al. US public concerns about the COVID-19 pandemic from results of a survey given via social media. *JAMA Intern Med* 2020; 180: 1020.
3. Qin L, Sun Q, Wang Y, et al. Prediction of number of cases of 2019 novel coronavirus (COVID-19) using social media search index. *Int J Environ Res Public Health* 2020; 17: 2365.
4. Levy P, Kohler M, McNicholas WT, et al. Obstructive sleep apnoea syndrome. *Nat Rev Dis Primers* 2015; 1: 15015.
5. Pepin JL, Bailly S and Tamisier R. Big data in sleep apnoea: opportunities and challenges. *Respirology* 2020; 25: 486–494.
6. Barker J, Oyefeso O, Koeckerling D, et al. COVID-19: community CPAP and NIV should be stopped unless medically necessary to support life. *Thorax* 2020; 75: 367.
7. Onder G, Rezza G and Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *JAMA* 2020; 323: 1775–1776.
8. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and Meta-analysis. *Int J Infect Dis* 2020; 94: 91–95.
9. Baker JG and Sovani M. Case for continuing community NIV and CPAP during the COVID-19 epidemic. *Thorax* 2020; 75: 368.
10. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med* 2019; 25: 44–56.
11. Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. *Lancet Respir Med* 2019; 7: 687–698.